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VORICONAZOLE COMPARED WITH LIPOSOMAL AMPHOTERICIN B
FOR EMPIRICAL ANTIFUNGAL THERAPY IN PATIENTS WITH NEUTROPENIA
AND PERSISTENT FEVER
THOMAS J. WALSH, M.D., PETER PAPPAS, M.D., DREW J. WINSTON, M.D., HILLARD M. LAZARUS, M.D.,
FINN PETERSEN, M.D., JOHN RAFFALLI, M.D., SAUL YANOVICH, M.D., PATRICK STIFF, M.D.,
RICHARD GREENBERG, M.D., GERALD DONOWITZ, M.D., AND JEANETTE LEE, PH.D.,
FOR THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES MYCOSES STUDY GROUP*

ABSTRACT
Background Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent
invasive fungal infections. Antifungal triazoles offer
a potentially safer and effective alternative.
Methods In a randomized, international, multicenter trial, we compared voriconazole, a new second-generation triazole, with liposomal amphotericin B for empirical antifungal therapy.
Results A total of 837 patients (415 assigned to
voriconazole and 422 to liposomal amphotericin B)
were evaluated for success of treatment. The overall
success rates were 26.0 percent with voriconazole
and 30.6 percent with liposomal amphotericin B (95
percent confidence interval for the difference, ¡10.6
to 1.6 percentage points); these rates were independent of the administration of antifungal prophylaxis
or the use of colony-stimulating factors. There were
fewer documented breakthrough fungal infections in
patients treated with voriconazole than in those
treated with liposomal amphotericin B (8 [1.9 percent] vs. 21 [5.0 percent], P=0.02). The voriconazole
group had fewer cases of severe infusion-related reactions (P<0.01) and of nephrotoxicity (P<0.001).
The incidence of hepatotoxicity was similar in the
two groups. Patients receiving voriconazole had
more episodes of transient visual changes than
those receiving liposomal amphotericin B (22 percent vs. 1 percent, P<0.001) and more hallucinations
(4.3 percent vs. 0.5 percent, P<0.001). Parenteral voriconazole was changed to the oral formulation in 22
percent of the voriconazole group, with a reduction
in the mean duration of hospitalization by one day in
all patients (P=0.17) but by two days in patients at
high risk (P=0.03).
Conclusions Voriconazole is a suitable alternative
to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever. (N Engl J Med 2002;346:225-34.)
Copyright © 2002 Massachusetts Medical Society.

I

NVASIVE fungal infections are important causes of morbidity and mortality among patients
receiving cancer chemotherapy or undergoing
bone marrow or stem-cell transplantation.1-3
Over the past two decades, empirical antifungal therapy with conventional amphotericin B or liposomal
amphotericin B has become the standard of care in
reducing invasive fungal infections in patients with
neutropenia and persistent fever.4-9 Amphotericin B,
however, is associated with significant dose-limiting
nephrotoxicity and infusion-related reactions. Liposomal amphotericin B is equivalent to conventional
amphotericin B for use as empirical antifungal therapy and significantly reduces proven invasive fungal
infections, nephrotoxicity, and infusion-related reactions.10,11 The high acquisition cost of liposomal amphotericin B, however, has limited the use of this less
toxic formulation of amphotericin B. Moreover,
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breakthrough fungal infections, infusion-related reactions, and nephrotoxicity still occur in patients receiving liposomal amphotericin B.
Antifungal triazoles are promising agents for empirical antifungal therapy.12,13 Fluconazole has been
studied for this indication, but its use is limited because it has a narrow antifungal spectrum restricted
to yeasts.14-16 Itraconazole also has been investigated.17 However, its oral administration is limited because of the erratic bioavailability of the capsule form
and the adverse gastrointestinal effects of the oral solution. Moreover, there has been limited experience
with the new parenteral formulation. The new generation of antifungal triazoles that includes voriconazole has a broad in vitro spectrum, potent in vivo
activity, a favorable safety profile, and excellent bioavailability.18-20 We reasoned that voriconazole, a second-generation triazole, might be as effective as
conventional or liposomal amphotericin B for empirical antifungal therapy, but less toxic.
METHODS
Study Design
The study was an open-label, prospective, randomized, multicenter, international comparative trial of voriconazole and liposomal amphotericin B, conducted between March 1998 and September 1999. The study was reviewed by an institutional review
board or ethics committee at each of the 73 participating centers.
Written informed consent was obtained from each patient or his
or her legal guardian before enrollment in the study. The data
safety and monitoring board of the National Institute of Allergy
and Infectious Diseases Mycoses Study Group was convened to
review data in order to monitor patient safety. A data-review committee composed of a panel of blinded investigators with expertise
in the study and treatment of fungal infections reviewed and classified all documented (proven and probable) fungal infections, using protocol-defined criteria.21
Enrollment, Stratification, and Randomization
Eligible patients were at least 12 years of age; had received chemotherapy for leukemia, lymphoma, or other cancers or had undergone transplantation of hematopoietic stem cells; and had received more than 96 hours of systemic antibacterial therapy while
continuing to have fever (oral temperature above 38°C within 24
hours before randomization) and neutropenia (an absolute neutrophil count below 500 cells per cubic millimeter for 96 hours
and below 250 cells per cubic millimeter within 24 hours before
randomization). Patients were not eligible if they had a documented invasive fungal infection at the time of randomization or
serum levels of aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, or bilirubin that were more than five times the
upper limit of normal.
Patients at each center were stratified according to their degree
of risk for fungal infection and the use or nonuse of systemic antifungal prophylaxis. Patients were randomly assigned to receive either
voriconazole or liposomal amphotericin B, in a 1:1 ratio, according
to a computer-generated randomization system with a two-perblock design. Patients at high risk were defined as those who had
received allogeneic hematopoietic stem-cell transplants or who
were receiving chemotherapy for relapsed leukemia. Other patients
were classified as being at moderate risk.

Administration of Study Drugs
Voriconazole was administered intravenously on day 1 as a loading dose of 6 mg per kilogram of body weight every 12 hours for
two doses and then continued at a maintenance dose of 3 mg per
kilogram intravenously every 12 hours (or 200 mg orally every 12
hours, after at least three days of intravenous therapy). Liposomal
amphotericin B was initiated and continued at 3 mg per kilogram
intravenously per day. After protocol-defined guidelines for evidence of fungal infection had been met, investigators were permitted to increase the dose of voriconazole to 4 mg per kilogram intravenously every 12 hours or 300 mg orally every 12 hours and
the dose of liposomal amphotericin B to 6 mg per kilogram intravenously per day. If toxic effects occurred, lowering of the dose
of liposomal amphotericin B to 1.5 mg per kilogram per day was
permitted. No dose reduction was permitted for voriconazole unless there had been a prior dose escalation. On the basis of the
assessment of the primary physician, patients who were unable to
tolerate or did not respond to the study drug were removed from
the clinical trial. Patients continued therapy for up to 3 days after
neutrophil recovery (defined as an absolute neutrophil count of
at least 250 cells per cubic millimeter), or up to a maximum of 12
weeks in those with documented invasive fungal infections. All infusion-related reactions were monitored prospectively with a previously validated bedside monitoring form.
Antifungal Activity and Pharmacokinetics of Voriconazole
Minimal inhibitory concentrations of voriconazole and amphotericin B were determined in a central reference laboratory according to the guidelines of the National Committee for Clinical
Laboratory Standards 22,23 for yeasts and filamentous fungi isolated
from patients with documented invasive fungal infections. Plasma
voriconazole levels were determined in each patient by high-performance liquid chromatography of blood collected twice weekly,
according to a minimal sampling strategy.24
Composite Outcome Score
Treatment was considered successful if the patient did not have a
breakthrough fungal infection, survived for seven days beyond the
end of therapy, did not discontinue therapy prematurely, had resolution of fever during the period of neutropenia, and was successfully treated for any base-line fungal infection. Encompassing at least
one end point from each earlier trial,6-8,11,14,15 this composite scoring
system has been used and validated in other studies of empirical antifungal therapy.10,16,17 Secondary analyses of individual composite
end points were exploratory assessments and were not intended to
be a primary determination of outcome superiority.
Statistical Analysis
Noninferiority was predefined as a difference in success rates between voriconazole and liposomal amphotericin B of no more than
10 percentage points. On the assumption of a success rate of 50 percent, a sample of 393 patients who could be evaluated in each treatment group (a total of 786) was required to demonstrate noninferiority at the two-sided significance level of 5 percent with a power
of 80 percent.25 Thus, a 95 percent confidence interval for the difference in response rates within 10 percentage points in either direction was required for voriconazole to be considered not inferior
to liposomal amphotericin B. On the assumption of a 10 percent
loss of patients from the modified intention-to-treat population, a
total sample size of 866 needed to be enrolled. The population for
the primary analysis (the modified intention-to-treat population)
was defined as the patients who were randomly assigned to treatment, who received one or more doses of study drug, and for whom
the data were sufficient to permit evaluation. The sample was also
sufficiently large that the study was prospectively projected to assess
the effect of the study drug on the prevention of invasive fungal infections, given the assumption of a 6 percent frequency of infection,
a reduction to 2 percent, and a two-tailed alpha level of 0.05.
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Outcome indicators were analyzed on the basis of the confidence interval around the difference in success rates and by the
Cochran–Mantel–Haenszel chi-square test in the modified intention-to-treat population. A 95 percent two-sided confidence interval was constructed around the difference in success rates between the two treatment groups. The rates of adverse events and
other safety-related variables were tabulated according to treatment
group, and selected variables were analyzed by the chi-square test
or Fisher’s exact test. A Kaplan–Meier analysis of time to defervescence was plotted.
The patients’ utilization of health care resources was prospectively studied. We hypothesized that the availability of the oral formulation of voriconazole would lead to earlier hospital discharge.
The total number of inpatient days was analyzed by the Wilcoxon
rank-sum test (two-sided).

RESULTS
Patient Population

A total of 849 patients received at least one dose
of study drug. Among the 837 patients in the modified intention-to-treat population, 415 received voriconazole and 422 received liposomal amphotericin
B. The study groups were similar with regard to age,
sex, race, underlying primary neoplastic disease, and
risk of fungal infection (Table 1). Antibacterial therapy, including use of aminoglycosides, use of antiviral
agents, and modifications of initial antibiotic therapy,
was also similar in the two treatment groups. Thirteen
patients in the voriconazole group and six patients
in the liposomal amphotericin B group had base-line
fungal infections documented within the first 24 hours
after entry to the study (Table 1).
Efficacy

The overall success rate according to the composite score and the response according to each of its
five components are shown in Table 2. The overall
success rate among patients in the modified intention-to-treat population was 26.0 percent for those
receiving voriconazole and 30.6 percent for those
receiving liposomal amphotericin B (95 percent confidence interval for the difference, ¡10.6 to 1.6 percentage points). This 95 percent confidence interval
falls just outside the predefined lower limit of ¡10
percentage points. Among the five components in the
composite score, the only significant difference was
found in the frequency of breakthrough fungal infections.
Documented breakthrough fungal infections occurred in 8 patients receiving voriconazole and 21
patients receiving liposomal amphotericin B (P=
0.02) (Table 3). There were fewer cases of documented breakthrough invasive aspergillosis, candidemia, and
dematiaceous mold infections among patients receiving voriconazole, and fewer cases of zygomycosis
among patients receiving liposomal amphotericin B.
We further evaluated the effect of breakthrough fungal
infections by examining 30-day mortality. Among

the 29 patients with breakthrough fungal infections,
14 (48.3 percent) died from invasive mycosis; in comparison, the overall mortality in this study was 12.9
percent (108 of 837, P<0.001).
The reduction in invasive fungal infections was particularly apparent in the stratified cohort of patients
at high risk (those with allogeneic transplants or relapsed leukemia) (Table 4). Among these patients,
those receiving voriconazole had fewer documented
breakthrough fungal infections than those receiving
liposomal amphotericin B (2 of 143 [1.4 percent] vs.
13 of 141 [9.2 percent], P=0.003). The protective
effect of voriconazole was also evident in the highrisk population among patients who were receiving
systemic antifungal prophylaxis: 1.2 percent of these
patients had invasive fungal infections, as compared
with 9.1 percent in the liposomal amphotericin B
group (P=0.02).
The most common documented base-line fungal
infection was candidemia, followed by pulmonary
aspergillosis, disseminated zygomycosis, and trichoderma fungemia. Similar proportions of base-line
fungal infections responded to voriconazole and liposomal amphotericin B (6 of 13 [46.2 percent]
and 4 of 6 [66.7 percent], respectively; P=0.63)
(Table 2).
There was no significant difference in overall mortality between the voriconazole and liposomal amphotericin B groups. However, among the patients
who died, more patients in the voriconazole group
than in the liposomal amphotericin B group died of
progressive underlying neoplastic disease (13 vs. 5,
P=0.06). There were also more deaths from bacterial
pneumonia or sepsis among the patients with progressive cancer.
There was a trend toward more frequent premature discontinuation of the study drug in the voriconazole group than in the liposomal amphotericin
B group. The number of patients discontinuing the
drug because of toxic effects was similar in the two
groups (19 in the voriconazole group and 23 in the
liposomal amphotericin B group). However, there
were more discontinuations due to lack of efficacy in
patients who received voriconazole (22 vs. 5, P=
0.001), with persistent fever being the most common
reason for withdrawal (14 vs. 2, P=0.002). None of
these fevers were due to documented breakthrough
fungal infections. Despite these withdrawals because
of fever, the overall frequency of resolution of fever
and the time to resolution of fever were virtually
identical in the two study groups according to Kaplan–Meier analysis (Fig. 1).
Effect of Risk Stratification on Outcome

Among patients at high risk, the overall success rate
was 32 percent for voriconazole and 30 percent for
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TABLE 1. DEMOGRAPHIC

AND

CLINICAL CHARACTERISTICS

CHARACTERISTIC

Age — yr
Mean
Range
Age group — no. (%)
<18 yr
18–44 yr
45–64 yr
»65 yr
Sex — no. (%)
Male
Female
Race — no. (%)
White
Black
Other
Risk category — no. (%)†
High
Moderate
Antifungal prophylaxis — no. (%)‡
Hematopoietic transplantation — no. (%)
Allogeneic
Autologous
Primary diagnosis — no. (%)
Newly diagnosed leukemia
Relapsed leukemia
Lymphoma
Multiple myeloma
Solid tumor
Other
Antibiotic treatment — no. (%)
Aminoglycosides
Antiviral agent
Modification of initial therapy
Cytokines — no. (%)§
Duration of neutropenia — days
Before randomization
Median
Range
Total duration
Median
Range
Base-line fungal infections — no.¶
Candida
Aspergillus
Other organisms
Duration of administration of study drug — days¿
Median
Range

OF THE

STUDY PATIENTS.*

VORICONAZOLE
(N=415)

LIPOSOMAL AMPHOTERICIN B
(N=422)

46.3
12–82

45.0
12–80

13
161
190
51

(3.1)
(38.8)
(45.8)
(12.3)

20
177
181
44

(4.7)
(41.9)
(42.9)
(10.4)

233 (56.1)
182 (43.9)

216 (51.2)
206 (48.8)

325 (78.3)
35 (8.4)
55 (13.3)

333 (78.9)
32 (7.6)
57 (13.5)

143
272
222
198
76
122

(34.5)
(65.5)
(53.5)
(47.7)
(18.3)
(29.4)

141
281
250
217
79
139

(33.4)
(66.6)
(59.2)
(51.4)
(18.7)
(32.9)

130
92
57
22
52
62

(31.3)
(22.2)
(13.7)
(5.3)
(12.5)
(14.9)

130
84
63
24
58
63

(30.8)
(19.9)
(14.9)
(5.7)
(13.7)
(14.9)

199
277
66
192

(48.0)
(66.7)
(15.9)
(46.3)

216
297
75
201

(51.2)
(70.4)
(17.8)
(47.6)

7.7
2.4–71

7.6
2.4–60

15.2
3.3–119
13
10
2
1

14.2
4.2–75
6
3
2
1

7
1–113

7
1–81

*Because of rounding, not all percentages add to 100.
†Patients at high risk had undergone allogeneic hematopoietic transplantation or had relapsed leukemia. Among patients with relapsed leukemia, 31 of 92 patients receiving voriconazole (34 percent)
and 27 of 84 patients receiving liposomal amphotericin B (32 percent) also underwent allogeneic
hematopoietic transplantation.
‡Antifungal prophylaxis was defined as treatment with systemically absorbed or parenterally administered antifungal agents for the prevention of invasive fungal infections before randomization.
§Cytokines were granulocyte colony-stimulating factor and granulocyte–macrophage colony-stimulating factor.
¶Invasive fungal infections (as defined by modified criteria of the European Organization for Research and Treatment of Cancer–Mycosis Study Group21) documented within 24 hours after study
entry are listed. One patient in the voriconazole group had disseminated zygomycosis, and one in the
amphotericin B group had trichoderma fungemia at base line. Among patients with base-line fungal
infections, 2 of 13 assigned to voriconazole (15 percent) received antifungal prophylaxis (fluconazole
in both cases), and 3 of 6 assigned to liposomal amphotericin B (50 percent) received antifungal
prophylaxis (fluconazole in 2 cases and low-dose deoxycholate amphotericin B in 1 case).
¿Ninety-two patients (22 percent) received the oral formulation of voriconazole.
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TABLE 2. RESPONSE

TO

EMPIRICAL THERAPY.

VORICONAZOLE
(N=415)

RESPONSE INDICATOR

Overall response — no. (%)
No breakthrough fungal infections within 7 days
of end of therapy — no. (%)
Survival 7 days after end of therapy — no. (%)*
No discontinuation due to toxicity or lack of efficacy
before recovery from neutropenia — no. (%)
Resolution of fever during neutropenia — no. (%)
Complete or partial response of patients with base-line fungal
infections by end of treatment — no./total no. (%)

LIPOSOMAL
AMPHOTERICIN B
(N=422)

POINT ESTIMATE FOR
PERCENT DIFFERENCE
(95% CONFIDENCE INTERVAL)
THE

108 (26.0)
407 (98.1)

129 (30.6)
401 (95.0)

¡4.5 (¡10.6 to 1.6)
+3.1 (0.6 to 5.5)

382 (92.0)
374 (90.1)

397 (94.1)
394 (93.4)

¡2.0 (¡5.5 to 1.4)
¡3.2 (¡7.0 to 0.5)

135 (32.5)
6/13 (46.2)

154 (36.5)
4/6 (66.7)

¡4.0 (¡10.4 to 2.5)
¡20.5 (¡67.0 to 25.9)

*The causes of death for patients in the voriconazole and liposomal amphotericin B groups, respectively, as assessed by the principal investigators, were as follows: progression of cancer (13 and 5 patients), respiratory failure (4 and 3 patients), renal failure (2 patients and
1 patient), sepsis (15 and 9 patients), bacterial pneumonia (7 patients and 1 patient), hemorrhage (0 and 6 patients), disseminated fungal
infection (1 patient and 2 patients), ventricular fibrillation (1 patient and 0), and other causes (5 and 4 patients).

liposomal amphotericin B (95 percent confidence interval for the difference, ¡9.0 to 12.4 percentage
points). By comparison, among patients at moderate
risk, the overall success rate was lower for voriconazole (23 percent) than for liposomal amphotericin B
(31 percent) (95 percent confidence interval for the
difference, ¡15.2 to ¡0.4 percentage points). This
difference in efficacy among patients at moderate
risk was due mainly to a disparity in mortality from
progressive cancer. Although these patients were at
lower risk for invasive fungal infections, they were
not at lower risk for death due to other causes, including cancer.
Safety and Tolerability
Infusion-Related Reactions

Abnormal vision characterized by a transient alteration in the perception of light was the most common
infusion-related toxic effect of voriconazole (Table
5). This effect was observed most frequently at the
time of the first infusion and disappeared during subsequent infusions. Patients receiving liposomal amphotericin B had more episodes of acute infusionrelated reactions than those receiving voriconazole.
Hepatotoxicity and Nephrotoxicity

There were no significant differences between the
study groups in hepatotoxicity, as measured by elevations in serum aspartate aminotransferase, alanine
aminotransferase, and alkaline phosphatase levels (Table 5). Serum bilirubin levels were more commonly
elevated in recipients of liposomal amphotericin B.
There was a greater frequency of azotemia among
patients receiving liposomal amphotericin B, as de-

fined by an elevation in the serum creatinine level to
more than 1.5 times the base-line value; however,
there was no significant difference in the frequency of
serum creatinine levels that were more than two
times the base-line value. There also was a greater
frequency of moderate hypokalemia (defined as a serum potassium level «3.0 mmol per liter) and severe
hypokalemia («2.5 mmol per liter) in patients receiving liposomal amphotericin B.
Visual Hallucinations and Other Toxic Effects

Visual hallucinations were more frequent in patients receiving voriconazole than in those receiving
liposomal amphotericin B (18 [4.3 percent] vs. 2 [0.5
percent], P<0.001). In most cases these effects were
distinct from infusion-related altered perception of
light. There were no differences between the groups
in the frequency of treatment-related rash or cardiacassociated adverse events.
Use of Health Care Resources

Ninety-two patients (22 percent) were able to receive the oral formulation of voriconazole. Patients
receiving voriconazole had a nonsignificant reduction
in the duration of hospitalization, with a median difference of one day (P=0.17). Patients at high risk
(those with allogeneic transplants or relapsed leukemia) who received voriconazole had a significant reduction in the duration of hospitalization with a median difference of two days (P=0.03).
Antifungal Activity and Pharmacokinetics of Voriconazole

Mean plasma voriconazole levels between 2 and
4 μg per milliliter were sustained throughout the
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TABLE 3. DOCUMENTED BREAKTHROUGH INVASIVE FUNGAL
INFECTIONS.*
VORICONVARIABLE

AZOLE

Organism and site (no. of cases)
Aspergillus species
Lungs
Sinuses
Central nervous system or skin
Disseminated
Total
Candida species
Disseminated
Blood
Total
Zygomycetes†
Lung
Nasal passages
Total
Dematiaceous molds‡
Blood
Lungs
Total
Total breakthrough invasive fungal infections
Demographic and clinical characteristics
Primary condition (no. of cases)
Acute leukemia
Multiple myeloma
Myelodysplasia
Lymphoma
Duration of neutropenia before infection
(days)
Median
Range
Duration of administration of study drug
before infection (days)
Median
Range
Systemic antifungal prophylaxis (no. of cases)

TABLE 4. DOCUMENTED BREAKTHROUGH FUNGAL INFECTIONS
DURING EMPIRICAL ANTIFUNGAL THERAPY,
ACCORDING TO RISK CATEGORY.

LIPOSOMAL
AMPHOTERICIN B
RISK GROUP

4
0
0
0
4

9
2
1
1
13

1
1
2

0
6
6

1
1
2

0
0
0

0
0
0
8

1
1
2
21§

ANTIFUNGAL
PROPHYLAXIS*

NO
ANTIFUNGAL
PROPHYLAXIS

TOTAL

no. of cases/total no. (%)

High risk†
Voriconazole
Liposomal amphotericin B
Moderate risk
Voriconazole
Liposomal amphotericin B
Total
Voriconazole
Liposomal amphotericin B

1/83 (1.2)
9/99 (9.1)

1/60 (1.7)
4/42 (9.5)

2/143 (1.4)‡
13/141 (9.2)‡

1/139 (0.7)
4/151 (2.6)

5/133 (3.8)
4/130 (3.1)

6/272 (2.2)§
8/281 (2.8)§

2/222 (0.9)
13/250 (5.2)

6/193 (3.1)
8/172 (4.7)

8/415 (1.9)¶
21/422 (5.0)¶

*Antifungal prophylaxis was defined as treatment with systemically absorbed or parenterally administered antifungal agents for the prevention of
invasive fungal infections before randomization.
†Patients at high risk had undergone allogeneic hematopoietic transplantation or had relapsed leukemia.

6
1
1
0

16
0
1
4

26
12–106

18
6–63

13
4–45
2

6
2–41
13

*Breakthrough invasive fungal infections were defined according to
modified criteria of the European Organization for Research and Treatment of Cancer–Mycosis Study Group.21
†The zygomycetes were one rhizopus species and one unidentified species that was histologically documented to have characteristic features of
zygomycetes.
‡The dematiaceous molds were one alternaria species and one unidentified species that was histologically documented to have the pigmented cell
walls that are characteristic of these organisms.
§P=0.02 for the comparison with the voriconazole group.

12-hour dosing interval. Approximately 75 percent
of the plasma voriconazole levels were between 1 and
7 μg per milliliter during the dosing interval. Among
15 isolates of candida species recovered from 10 patients with fungemia, only 1 isolate (Candida glabrata) was associated with a minimal inhibitory concentration of voriconazole (4 μg per milliliter) that
exceeded plasma levels achieved by voriconazole at
the dosages used in this study. This isolate was also
resistant to other antifungal triazoles. Among five

‡P=0.003 for the comparison of voriconazole with amphotericin B.
§P not significant.
¶P=0.02 for the comparison of voriconazole with amphotericin B.

isolates of aspergillus species, the minimal inhibitory
concentration of voriconazole was within achievable
levels.
DISCUSSION

In this randomized comparison of voriconazole
with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent
fever, voriconazole did not fulfill the protocol-defined
criteria for noninferiority to liposomal amphotericin
B with respect to overall response to empirical therapy, since the 95 percent confidence limit of ¡10.6
percentage points fell just outside the predefined lower bound of ¡10 percentage points. However, examination of the individual elements of the composite
score for success indicated that the two treatments
were similar and that voriconazole was superior in
reducing documented breakthrough fungal infections, infusion-related toxicity, and nephrotoxicity.
The activity of voriconazole in the prevention of
breakthrough fungal infections in this study is consistent with its efficacy in a recently completed clinical trial involving primary treatment of documented
invasive aspergillosis.26 These effects may be related
to the combination of its potent in vitro antifungal
activity (indicated by low minimal inhibitory concentrations against most yeasts and filamentous fungi)
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Figure 1. Kaplan–Meier Estimates of the Time to Resolution of Fever in Patients with Neutropenia and Persistent Fever
Who Were Randomly Assigned to Receive Voriconazole or Liposomal Amphotericin B as Empirical Antifungal Therapy.

and its pharmacokinetic properties.12,13,26-28 The low
molecular weight of voriconazole (349.3) may permit
penetration into the endobronchial-lining fluid and
other mucosal surfaces.28 The fact that the plasma
pharmacokinetics in our study demonstrated circulating voriconazole levels well above the minimal inhibitory concentration for most fungal pathogens during its 12-hour dosing interval may also contribute
to its clinical antifungal activity.
Empirical antifungal therapy with voriconazole
should be used in patients with persistent neutropenia, who are at high risk for invasive antifungal infections.29-32 In the prospectively defined high-risk
group in our study, the overall response rate among
patients who received voriconazole was similar to
the rate among those who received liposomal amphotericin B, and the frequency of breakthrough
fungal infections was significantly reduced in the
voriconazole group.
The open-label design of this trial permitted us to
evaluate the effect of oral voriconazole on time of
discharge, but it may have created a bias in favor of
liposomal amphotericin B, with which there is extensive clinical experience. Significantly more patients
receiving voriconazole than those receiving liposomal amphotericin B were removed prematurely from
the study because of persistent fever in the absence

of evidence of fungal infection, despite similar frequencies of fever in both groups. A similar pattern was seen
in a large, randomized, open-label study comparing
amphotericin B and fluconazole for candidemia, in
which patients receiving fluconazole were removed
from the study because of persistent fever, despite clinical stability and repeatedly negative blood cultures.33
In this study, the infusion-related reactions to voriconazole and liposomal amphotericin B were characterized by prospective bedside monitoring of more
than 10,000 infusions. Although liposomal amphotericin B is well known to have significantly lower infusion-related toxicity than conventional amphotericin
B,10 severe acute reactions have been described.34-37
In our study, 65 percent of the instances of discontinuation of liposomal amphotericin B were due to a
syndrome that included dyspnea, hypoxemia, urticaria, and chest, abdominal, or flank pain. By comparison, the only significant infusion-related reaction to
voriconazole was transient photopsia, which was not
associated with discontinuation of therapy.
More patients receiving liposomal amphotericin B
had azotemia (defined as a serum creatinine level more
than 1.5 times the base-line level), hypokalemia, or
hypomagnesemia. However, there was no significant
difference between the groups in the proportion of
patients with serum creatinine levels of more than

N Engl J Med, Vol. 346, No. 4 · January 24, 2002 · www.nejm.org · 231

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 22, 2015. For personal use only. No other uses without permission.
Copyright © 2002 Massachusetts Medical Society. All rights reserved.

The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne

TABLE 5. INFUSION-RELATED REACTIONS AND LABORATORY ABNORMALITIES IN PATIENTS
TREATED WITH VORICONAZOLE OR LIPOSOMAL AMPHOTERICIN B.

RESPONSE

VORICONAZOLE
(N=415)

LIPOSOMAL
AMPHOTERICIN B
(N=422)

P
VALUE*

no./total no. (%)

Infusion-related reactions†
Abnormal vision
Chest pain
Abdominal pain
Back pain
Flank pain
Dyspnea
Anaphylactoid reaction
Flushing
Sweating
Urticaria
Cyanosis
Chills
Cardiac arrest
Nausea
Laboratory abnormalities
Serum creatinine during therapy
>1.5¬ base line
>2.0¬ base line
Nephrotoxicity with concomitant nephrotoxic drugs‡
0 or 1 drug
»2 drugs
»3 drugs
Hypokalemia
Potassium «3.0 mmol/liter
Potassium «2.5 mmol/liter
Hypomagnesemia§
Magnesium «0.75 mg/dl
Magnesium «0.60 mg/dl
Serum alkaline phosphatase
>3¬ the base-line value¶
>5¬ the base-line value¿
Serum aspartate aminotransferase
>3¬ the base-line value¶
>5¬ the base-line value¿
Serum alanine aminotransferase
>3¬ the base-line value¶
>5¬ the base-line value¿
Serum bilirubin during therapy
»1.5¬ base line
»3.0¬ base line

91
1
1
0
1
3
0
14
3
1
0
57
1
39

(21.9)
(0.2)
(0.2)

3
17
12
14
8
37
7
46
9
3
2
126
0
53

(0.2)
(0.7)
(3.4)
(0.7)
(0.2)
(13.7)
(0.2)
(9.4)

(0.7)
(4.0)
(2.8)
(3.3)
(1.9)
(8.8)
(1.7)
(10.9)
(2.1)
(0.7)
(0.5)
(29.9)

<0.001
<0.001
0.002
<0.001
0.038
<0.001
0.02
<0.001

<0.001

(12.6)

43 (10.4)
29 (7.0)

80 (19.0)
32 (7.6)

42/372 (11.3)
6/42 (14.3)
2/4 (50.0)

37/381 (9.7)
16/241 (39.0)
3/5 (60.0)

68 (16.4)
10 (2.4)

131 (31.0)
21 (5.0)

261 (62.9)
65 (15.7)

275 (65.2)
72 (17.1)

0
12 (2.9)

2 (0.5)
18 (4.3)

0
37 (8.9)

0
27 (6.4)

1 (0.2)
29 (7.0)

0
34 (8.1)

73 (17.6)
40 (9.6)

97 (23.0)
46 (10.9)

<0.001

0.01
<0.001
<0.05

0.05

*P values indicating significant differences are shown.
†A total of 10,398 infusions were prospectively monitored: 6053 in the voriconazole group and
4345 in the liposomal amphotericin B group.
‡Nephrotoxic drugs were aminoglycosides, cyclosporine, and foscarnet.
§To convert the values for magnesium to millimoles per liter, multiply by 0.5.
¶Figures are for patients with base-line values 2 to 5 times the upper limit of normal.
¿Figures are for patients with base-line values <2 times the upper limit of normal.
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two times base line, a result consistent with the substantially lower nephrotoxicity of liposomal amphotericin B in comparison with that of conventional
amphotericin B. Voriconazole was not associated with
any increase in the frequency of hepatic or renal abnormalities. The low frequency of hepatotoxicity with
empirical therapy in our study may not pertain in
patients undergoing more prolonged treatment for
proven infection. In addition to its lower rates of
nephrotoxicity and hepatotoxicity, the reliable oral bioavailability of voriconazole may make possible earlier
hospital discharge and substantial cost savings in selected patients.
This study demonstrates that voriconazole, a second-generation triazole, is an appropriate agent for
empirical antifungal therapy and that its use may reduce the frequency of proven breakthrough fungal
infections, preserve renal function, and reduce the
frequency of acute infusion-related toxic effects. Formulations of amphotericin B have been the standard
of empirical antifungal therapy for nearly 20 years.
As this study shows, a second-generation triazole can
be used in lieu of amphotericin B for early antifungal
therapy.
Supported in part by grants from the National Institute of Allergy and
Infectious Diseases Mycoses Study Group (NO1-AI-65296) and Pfizer
Global Research and Development.
Dr. Walsh reports receiving consulting fees from Pfizer in 2001.
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